Axios Biosciences

Cambridge, United States Founded: 2009 • Age: 17 yrs
Creates innovative platforms for anti-cancer drug development.
Request Access

About Axios Biosciences

Axios Biosciences is a company based in Cambridge (United States) founded in 2009 by Douglas McMillin and Ashraf Haque. It operates as a B2B. Axios Biosciences operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Korro Bio, among others.

  • Headquarter Cambridge, United States
  • Founders Douglas McMillin, Ashraf Haque
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Latest Funding Round
    $288.7 K (USD), Grant

    Sep 09, 2013

  • Investors
    HHS

    & 1 more

  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Axios Biosciences

  • Total Funding
  • Total Rounds 2
  • Last Round Grant — $288,695
  • First Round
  • Investors Count 2
Date Amount Transaction Name Valuation Lead Investors Investors
Sep, 2013 Amount Grant - Axios Biosciences Valuation

investors

HHS
Jul, 2010 Amount Grant - Axios Biosciences Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Axios Biosciences

Axios Biosciences has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS and MassChallenge. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Early-stage entrepreneurs are accelerated through MassChallenge's program.
Founded Year Domain Location
Public health and human services are overseen by HHS.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Axios Biosciences

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Axios Biosciences

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Axios Biosciences Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Axios Biosciences

Axios Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Korro Bio, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Antibody-siRNA complexes are developed for cancer treatment.
domain founded_year HQ Location
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
domain founded_year HQ Location
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
domain founded_year HQ Location
Developing novel drugs based on a proteome-wide ligand and target discovery platform
domain founded_year HQ Location
RNA-editing technologies are provided for precision medicine applications.
domain founded_year HQ Location
Dental implants and regenerative dentistry products are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Axios Biosciences

Frequently Asked Questions about Axios Biosciences

When was Axios Biosciences founded?

Axios Biosciences was founded in 2009 and raised its 1st funding round 1 year after it was founded.

Where is Axios Biosciences located?

Axios Biosciences is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.

What does Axios Biosciences do?

Axios Biosciences, led by Douglas McMillin as Co-Founder, President, Ashraf Haque as Co-Founder, specializes in advancing biotech innovations, drug development, oncology, and anti-cancer platforms. Creates innovative platforms for anti-cancer drug development. The team drives innovation, quality service, and sustainable practices to achieve excellence and client satisfaction.

Who are the top competitors of Axios Biosciences?

Axios Biosciences's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.

Who are Axios Biosciences's investors?

Axios Biosciences has 2 investors. Key investors include HHS, and MassChallenge.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available